Compare Hilton Hotels Corporation Common Stock (HLT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Incyte Corporation — how do they compare? Hilton Hotels Corporation Common Stock trades at $314 (market cap $70.82B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.9× Incyte Corporation's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HLT | INCY | |
|---|---|---|
Market Cap | $70.82B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $129.93 |
52-Week Low | $256.75 | $81.61 |
Enterprise Value | $83.83B | $20.04B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.16, up 3.91% over 24 hours, with a bullish analyst consensus of 57% buy ratings and a $352 price target. Recent earnings have consistently beaten estimates, with Q2 2026 EPS at $2.29 matching expectations. The stock shows bearish technical signals but strong fundamentals, including revenue growth to $12.04B in 2025 and a net income margin of 12.69%. However, rising debt levels and a high P/E ratio of 46.21 pose valuation concerns.
The outlook for HLT is positive due to robust travel demand and a growing hotel pipeline, though premium valuation and increasing debt require caution. Investment opportunity lies in sustained earnings growth and capital returns, while risks include economic sensitivity and labor disputes, as highlighted by ongoing strikes and soft Q3 guidance affecting investor sentiment.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
